newsfilter
← Latest News
GlobeNewswire·

Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat

Cyclerion eligible to receive up to $585 million in potential future development and commercial milestone payments, and tiered sales-based royalties Praliciguat out-licensing further enables Cyclerion's strategic focus on CNS, including first-in-class